Your browser doesn't support javascript.
loading
High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology.
Chong, Lauren C; Ben-Neriah, Susana; Slack, Graham W; Freeman, Ciara; Ennishi, Daisuke; Mottok, Anja; Collinge, Brett; Abrisqueta, Pau; Farinha, Pedro; Boyle, Merrill; Meissner, Barbara; Kridel, Robert; Gerrie, Alina S; Villa, Diego; Savage, Kerry J; Sehn, Laurie H; Siebert, Reiner; Morin, Ryan D; Gascoyne, Randy D; Marra, Marco A; Connors, Joseph M; Mungall, Andrew J; Steidl, Christian; Scott, David W.
Affiliation
  • Chong LC; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
  • Ben-Neriah S; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
  • Slack GW; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
  • Freeman C; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
  • Ennishi D; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
  • Mottok A; Institute of Human Genetics, University of Ulm and Ulm University Medical Center, Ulm, Germany.
  • Collinge B; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
  • Abrisqueta P; Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Barcelona, Spain.
  • Farinha P; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
  • Boyle M; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
  • Meissner B; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
  • Kridel R; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Gerrie AS; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
  • Villa D; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
  • Savage KJ; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
  • Sehn LH; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
  • Siebert R; Institute of Human Genetics, University of Ulm and Ulm University Medical Center, Ulm, Germany.
  • Morin RD; Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada; and.
  • Gascoyne RD; Canada's Michael Smith Genome Sciences Centre, Vancouver, BC, Canada.
  • Marra MA; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
  • Connors JM; Canada's Michael Smith Genome Sciences Centre, Vancouver, BC, Canada.
  • Mungall AJ; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
  • Steidl C; Canada's Michael Smith Genome Sciences Centre, Vancouver, BC, Canada.
  • Scott DW; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
Blood Adv ; 2(20): 2755-2765, 2018 10 23.
Article in En | MEDLINE | ID: mdl-30348671
Genomic rearrangements in the MYC locus occur in ∼12% of lymphomas with diffuse large B-cell lymphoma (DLBCL) morphology and are associated with inferior outcome. Previous studies exploring MYC rearrangements have primarily used fluorescence in situ hybridization (FISH) assays to characterize break-apart status but have rarely examined breakpoint location, and in some cases have not examined partner identity. We performed targeted sequencing of MYC, BCL2, BCL6, and the immunoglobulin (IG) loci in 112 tumors with DLBCL morphology harboring MYC rearrangement. We characterized the location of the MYC rearrangement at base pair resolution and identified the partner in 88 cases. We observed a cluster of breakpoints upstream of the MYC coding region and in intron 1 (the "genic cluster"). Genic cluster rearrangements were enriched for translocations involving IGH (80%), whereas nongenic rearrangements occurred mostly downstream of the MYC gene with a variety of partners, including IGL and IGK Other recurrent partners included BCL6, ZCCHC7, and RFTN1, which has not previously been described as a MYC partner. We compared 2 commercially available FISH break-apart assays for the MYC locus and observed discordant results in 32% of cases examined, including some with MYC-IGL and MYC-IGK rearrangements. In cases of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement (HGBL-DH), so-called "double-hit" lymphomas, the majority of MYC rearrangements had non-IG partners (65%), with breakpoints outside the genic cluster (72%). In patients with de novo HGBL-DH of DLBCL morphology, MYC-IG rearrangements showed a trend toward inferior time to progression and overall survival compared with MYC-non-IG rearrangements. Our data reveal clinically relevant architecture of MYC rearrangements in lymphomas with DLBCL morphology.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Gene Rearrangement / Proto-Oncogene Proteins c-myc / Lymphoma, Large B-Cell, Diffuse Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Blood Adv Year: 2018 Type: Article Affiliation country: Canada

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Gene Rearrangement / Proto-Oncogene Proteins c-myc / Lymphoma, Large B-Cell, Diffuse Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Blood Adv Year: 2018 Type: Article Affiliation country: Canada